Amgen Keeps Win Over Regeneron Bid to Block Eylea Biosimilar (1)

Regeneron Pharmaceuticals Inc. failed to convince the Federal Circuit to block an Amgen Inc. biosimilar of Eylea while the competitors duke it out in a patent lawsuit.

Amgen’s biosimilar formulation is distinct from both the Regeneron patent covering Eylea and from the other biosimilars at issue in litigation that’s been consolidated in a West Virginia federal court, the US Court of Appeals for the Federal Circuit said in a precedential opinion issued Friday.

“Amgen had discovered a way to prepare and formulate the active ingredient, aflibercept, in a manner that eliminates the need for a separate buffer component,” Judge Alan ...